BEIGENE (06160) saw its shares rise by 6.08% in early trading, reaching HK$209.40, with a trading volume of HK$725 million.

The company recently reported its financial results, with Q3 revenue surpassing RMB 10 billion for the first time, reaching RMB 10.077 billion, a year-on-year increase of 41.1%. Operating profit stood at RMB 746 million, while net profit attributable to shareholders was RMB 689 million, and adjusted net profit was RMB 708 million. The strong performance was driven by robust sales growth of its BTK inhibitor Brukinsa (zanubrutinib) and PD-1 inhibitor tislelizumab, along with increased revenue from Amgen-authorized products.

Bank of Communications International raised its net profit forecast for BEIGENE by 3% to 52% based on Q3 results, citing more optimistic expectations for operating expense ratios. Haitong International also revised its revenue projections for 2025–2027 to $5.3 billion, $6.4 billion, and $7.1 billion, respectively, reflecting a compound annual growth rate of 23%, as zanubrutinib's sales in the US and Europe exceeded expectations.